Posters

Treatment of severe lens subluxation by femtosecond laser and modified four-point ciliary sulcus suture fixation combined with capsular tension ring

Poster Details

First Author: J.Cai CHINA

Co Author(s):    L. Wu                    

Abstract Details

Purpose:

To present techniques of treating severe lens subluxation by femtosecond laser capsulorhexis and modified four-point ciliary sulcus suture fixation combined with standard capsular tension rings (CTRs).

Setting:

Shanghai Xinshijie Zhongxing Eye Hospital, Shanghai, China.

Methods:

This study comprised 4 patients, 4 eyes with traumatic lens subluxation greater than 180 degrees. All patients received femtosecond laser capsulorhexis and phacoemulsification assisted by capsular hooks. Then they received surgery of standard capsular tension rings (CTRs) implantation combined with modified four-point ciliary sulcus suture fixation, which directly sutured the capsular bag with 10-0 polypropylene enclosing haptic and CTR together.

Results:

All patients were followed up for 1–6 months. The position of IOLs were good and well-centred. There were no significant complications such as intraocular bleeding, capsule rupture, CTR dislocation or thread broken etc. during the operation. During the follow-up, none of the patients had major complications, such as retinal detachment, macular edema, choroidal detachment, glaucoma, obvious corneal edema, IOL tilt, rotation or decentration, no suture knots erosion or endophthalmitis.

Conclusions:

This is a safe and easy technique. Femtosecond laser makes capsulorhexis easier, safer and fewer complications in patients who have large subluxation of lens. It requires no scleral flap, and uses standard simple CTR, which is easier to manipulate than modified CTRs, like Ahmed or Cionni CTR. It has 3 square knots holding the full thickness of sclera with 3mm in width, holds the CTR-IOL complex more steadily and the knots are buried in sulcus, it avoids or decreases complications other fixation techniques may have in the long run.

Financial Disclosure:

None